Showing 15 posts of 55 posts found.


US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute

April 26, 2018
Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …


New hepatitis C combo boasts 97% cure rate for just $300

April 12, 2018
Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …


Long-running, $2.5bn lawsuit swings in Gilead’s favour

February 19, 2018
Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …


Gilead launches hep C drug Sovaldi in China at one-fifth of US price

November 29, 2017
Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi

Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …


FDA approves first two antiviral hep C drugs for paediatric patients

April 10, 2017
Sales and Marketing FDA, harvoni, hepatitis C, sovaldi

The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …


Judge reverses verdict in MSD/Gilead hepatitis C dispute

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi

A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …


Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access

May 11, 2016
Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi

Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …


Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016
Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …

Sovaldi bottle

Gilead’s Sovaldi wins Drug Discovery of the Year Award

December 16, 2015
Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …

Gilead sign

Gilead awaits EU decision on hep C combo treatment

December 8, 2015
Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …

FDA image

FDA sued over failure to disclose Sovaldi data

June 30, 2015
Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi

Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …

Sovaldi image

China rejects Gilead’s Sovaldi patent

June 24, 2015
Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi

Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …


The Pharmafocus debate: Is the price of new hepatitis C treatments fair?

April 27, 2015
Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi

YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …

Gilead image

Gilead presents new Sovaldi data

April 23, 2015
Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi

Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …

BMS image

BMS resubmits hepatitis C drug

March 13, 2015
Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi

Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …

Latest content